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Abstract
Erythropoietin (EPO) is the major hormone stimulating the production and differentiation of red blood cells. EPO is
used widely for treating anemia of critical illness or anemia induced by chemotherapy. EPO at pharmacological
doses is used in this setting to raise hemoglobin levels (by preventing the apoptosis of erythroid progenitor cells)
and is designed to reduce patient exposure to allogenic blood through transfusions. Stroke, heart failure, and acute
kidney injury are a frequently encountered clinical problem. Unfortunately, in the intensive care unit advances in
supportive interventions have done little to reduce the high mortality associated with these conditions. Tissue
protection with EPO at high, nonpharmacological doses after injury has been found in the brain, heart, and kidney
of several animal models. It is now well known that EPO has anti-apoptotic effects in cells other than erythroid
progenitor cells, which is considered to be independent of EPOs erythropoietic activities. This review article
summarizes what is known in preclinical models of critical illness and discusses why this does not correlate with
randomized, controlled clinical trials.
Introduction
Inflammation, renal failure, or blood loss due to frequent
phlebotomies, gastric stress bleeding, coagulation disor-
ders, or surgical procedures [1] often results in anemia in
patients attending the intensive care unit (ICU). It is well
established that the bone marrow of critically ill patients is
able to respond to exogenously administered erythropoie-
tin (EPO) to cause a significant increase in reticulocyte
c o u n ta n ds e r u mt r a n s f e r r i nreceptor concentration [2].
However, during the past two decades, our understanding
of the actions of EPO has shifted from a belief that the
hormone acts exclusively on erythroid progenitor cells to
the knowledge that this agent exerts significant protection
in conditions, such as sepsis, hemorrhagic shock, and
ischemia/reperfusion injury (IRI) [3-9]. Many clinical set-
tings are associated with IRI in the ICU. These include
surgical procedures, transplantation, trauma-hemorrhage,
and sepsis, among others. From a pathophysiologic per-
spective, ischemia and the associated tissue hypoxia leads
to cell death, which are mediated by fundamental altera-
tions in cellular homeostasis. Although no single factor
has been identified as the critical mediator of cell death,
depletion of cellular energy stores plays a major role [10].
Reestablishment of blood flow to an organ(s) after ische-
mia (reperfusion) is essential for the recovery and survival
o ft h ep r e v i o u s l yi s c h e m i ct i s s u e .H o w e v e r ,r e p e r f u s i o n
itself often is harmful, because highly reactive molecules
are produced that add injury to the previously ischemic
organ (termed reperfusion injury). Furthermore, reperfu-
sion can result in systemic alterations caused by the
release/generation of vasoactive and/or proinflammatory
mediators and cytokines (e.g., interleukin-6 [IL-6], tumor
necrosis factor [TNF], high mobility group box protein-1
[HMGB-1]) within the previously ischemic tissue [11].
These events ultimately provoke a systemic inflammatory
response syndrome (SIRS), which will invariably cause
additional, remote organ injury (e.g., acute respiratory dis-
tress syndrome [ARDS]) [12]. The following review will
highlight the experimental and clinical evidence for a tis-
sue protective benefit of EPO, as opposed to its use for the
treatment of anemia (see [13] for review), following
various types of tissue injury.
Experimental evidence
The brain
EPO and its receptor (EPOR) are weakly expressed in the
human brain. However, their local production is rapidly
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provided the original work is properly cited.induced in response to acute hypoxia, as evidenced by the
increased expression of EPO in cerebrospinal fluid (CSF)
or postmortem brain tissue in humans with stroke and
hypoxia [14,15]. The first evidence that EPO is able to
protect tissues/organs comes from several models of
ischemic injury within the central nervous system (CNS).
Cultured hippocampal and cerebral cortical neurons trea-
ted with EPO (100 pg/ml) were protected from glutamate
neurotoxicity in a dose-dependent manner [16]. This
protection was completely reversed by co-application of a
soluble EPOR capable of binding and chelating EPO.
Occlusion of the common carotid arteries in a gerbil
induces a significant learning disability, which upon infu-
sion of EPO into the lateral ventricles of these gerbils
prevented the ischemia-induced learning disability and
prevented the degeneration of hippocampal CA1 neurons
[8]. Similarly, an infusion of soluble EPOR into animals
that were only given a mild ischemic insult, which was
insufficient to produce any damage by itself, caused CA1
neuronal degeneration. Using transgenic mice that con-
stitutively express human EPO in the brain, without
inducing excessive erythrocytosis, Kilic et al. [17] demon-
strated that brain-specific overexpression of human EPO
is associated with reductions in postischemic infarct
volume and functional deficits and that the neuroprotec-
tive actions of EPO can be separated, at least in part,
from its hematopoietic effects.
Despite previous evidence, it is now believed that EPO
crosses the blood-brain barrier (BBB) in an injured brain.
The first evidence for a neuroprotective effect of EPO by
a peripheral route of administration was provided by
Brines et al. (2000), who demonstrated in a focal stroke
model a significant reduction in infarct volume by an
intraperitoneally applied high dose of EPO (5000 IU/kg)
up to 6 hours after reperfusion. Immunohistochemical
detection of biotinylated EPO 5 hours after its intraperi-
toneal injection further provided evidence that EPO
crosses the BBB [18]. EPO not only crosses the BBB but
also can ameliorate BBB dysfunction evoked by IRI, as
s h o w ni nam o u s em o d e lo fa c u t ei s c h e m i cs t r o k e[ 1 9 ] .
Besides, EPO has been reported to promote factors for
angiogenesis, such as Tie-2 and angiopoietin-2, which
may assist with the restoration of cerebral blood flow to
preischemic levels [20].
These studies not only indicate that the survival of
neurons after an ischemic insult is dependent on the
formation of endogenous EPO but also indicate that
exogenous EPO may protect the brain and, possibly,
other tissues against IRI.
Cardiovascular system
In 2004, the expression of EPOR was thought to have
been discovered in the rat heart [21] and a year later in
the human heart [22], although expression of the EPOR
in the heart remains inconclusive due to the poor
specificity of the antibodies used for the immunostaining
[23]. Before this knowledge, work on the heart was well
underway and it had already been shown that EPO is
able is reduce the increase in caspase activation and the
subsequent apoptotic cell death caused by hypoxia and
oxidative stress in rat ventricular myoblasts (H9C2 cells)
[3,24]. The potential protective role of EPO in animal
models of myocardial infarction has been assessed and
beneficial effects have been observed regardless of
whether EPO was administered before ischemia, at the
onset of ischemia, or at reperfusion. A single bolus injec-
tion of EPO (5,000 IU/kg) 24 hours before the ischemic
insult remarkably reduced infarct size and neutrophil
infiltration [25]. We have reported that the administra-
tion of low doses of EPO (300 IU/kg i.v.) acutely upon
reperfusion reduces the infarct size caused by coronary
occlusion and reperfusion in the rat [3]. Similarly,
chronic administration of EPO (5,000 IU/kg i.p.), daily
for 7 days after myocardial ischemia, attenuates cardio-
myocyte loss by approximately 50% [5]. There have been
only two studies, thus far, comparing the protective
effects of EPO when administered at different time
points. Apoptosis was found to be further attenuated
when EPO was administered after the start of reperfusion
rather than just before ischemia [26]. Parsa et al. (2004)
reported that the most significant protection was noted
when EPO was given 12 hours before ischemia than
when given at the onset of ischemia or reperfusion in
rabbits [27]. Although there is clear evidence that EPO
can prevent apoptosis in ventricular myoblasts and cardi-
omyocytes, as described above, endothelial cells express
EPOR and hence, anti-apoptotic signaling can persist in
the presence of EPO, which makes endothelial cells more
resistant to ischemia-induced cell death [28]. Overall,
these results suggest that EPO treatment is effective for
both prevention and treatment of the ischemic episode.
The role of EPOR in cardioprotection has been investi-
gated using transgenic animal models. Transgene-rescued
EPOR null mutant mice when subjected to IRI showed a
larger infarct size and reduced left ventricular (LV) func-
tion compared with wild-type mice with intact EPOR [29].
Tightly integrated with cardiac performance, pulmonary
function also is enhanced during EPO administration,
especially in the setting of IRI of the lung, thanks to EPO’s
ability to decrease TNF-a expression and inhibit leukocyte
infiltration in lung tissue [30].
The therapeutic relevance of EPO in the clinical setting
of cardiovascular diseases has been confirmed by studies
in which EPO treatment was started 3 or 6 weeks after
induction of myocardial infarction, when heart failure
was fully established in mice [31,32]. In both reports,
chronic EPO treatment significantly improved cardiac
function and, interestingly, EPO’s beneficial effects lasted
for another 4 weeks even after EPO treatment was
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3-weekly administration of low-dose EPO (equivalent to
80 U/kg) after myocardial infarction (with a permanent
coronary artery ligation) did not raise hematocrit levels
but was able to improve cardiac function significantly.
Such a low-dose of EPO was demonstrated as being able
to induce neovascularization of the infarcted tissue, and
this could, in part, be responsible for the tissue protective
properties of EPO on cardiac function [33]. However,
t h i si sn o tt h ef i r s tt i m et h a tE P Oh a sb e e ns h o w nt ob e
able to stimulate the proliferation of a number of cells,
including endothelial and tubular epithelial cells. Circu-
lating bone marrow-derived endothelial progenitor cells
(EPCs) promote vascular reparative processes. EPO has
been shown to be a mediator for the mobilization and
proliferation of EPCs in both ischemic and nonischemic
tissue [34-36]. However, neovascularization only seems
to occur in ischemic tissue [6,36]. For instance, patients
with unstable coronary heart disease have significantly
higher serum levels of EPO, which has been shown to be
associated with an increased amount of functionally
active EPCs [6]. We have demonstrated that precondi-
tioning mice with EPO (1,000 U/kg/day for 3 days) in a
protocol that has been shown to mobilize EPCs [6] was
associated with a greater degree of renal protection in a
model of renal IRI (30 minutes ischemia and 24 hours
reperfusion) compared with the administration of a single
dose of EPO (1,000 U/kg) at the time of reperfusion [6].
Lipsic et al. also administered a higher dose of EPO
(equivalent to 8,000 IU/kg), which significantly increased
hematocrit levels but with the added benefit of further
improvements in cardiac function and neovascularization
compared with the low-dose EPO group [33]. This could
be the result of the following one of two (or both) rea-
sons: 1) an increased oxygen delivery capacity to the
injured tissue as a result of increased numbers of circu-
lating erythrocytes; or 2) a dose-dependent effect of
EPO’s tissue protective properties. This particular study
has demonstrated that EPO treatment improves cardiac
function and induces neovascularization in postmyocar-
dial infarction heart failure, even at doses that do not
increase hematocrit. EPOs ability to improve cardiac
function, independent of erythropoiesis and the mobiliza-
tion of bone marrow-derived cells, has been recently con-
firmed by a study demonstrating that EPO prevented
cardiomyocyte apoptosis and stimulated angiogenesis
after myocardial infarction by direct upregulation of
angiogenic factors, such as VEGF and angiopoietin-1
expression [37].
Although time-limited treatment with high-dose EPO
may be beneficial and safe during acute ischemic injury, if
prolonged therapy is required (for instance during heart
failure), drug regimens using low-dose EPO (or EPO
devoid of erythropoietic effects) may be more suitable to
avoid the adverse effects of the treatment (see [38] for
review).
Kidney
Although it has been recognized for many years that EPO
is produced in the adult kidney, mainly by peritubular
interstitial cells and tubular epithelial cells, it was not
until 1999 that the EPOR was reported to be expressed
in tubular epithelial cells [39]. When rats were subjected
to 45 minutes of bilateral renal ischemia, there was sig-
nificant renal dysfunction and damage to the tubular
architecture. However, this process was prevented by
administration of 3,000 IU/kg of EPO 24 hours before
the ischemic insult, which was attributed to an attenua-
tion of apoptosis [40]. In a similar study, Vesey et al.
were able to demonstrate an attenuation of apoptosis in
the proximal tubule, proximal convoluted tubule, and
outer medullary thick ascending limb with the adminis-
tration of 5,000 IU/kg of EPO 30 min before a 30-min
ischemic insult [41]. This beneficial effect of EPO was
secondary to inhibition of the activities of caspase-3, -8,
and -9 in the proximal tubule [9], as well as inflammation
induced by neutrophils [7]. The protection afforded by
EPO against renal IRI also might be partly due to its anti-
oxidant effects, because EPO administration before the
onset of renal ischaemia has been shown to induce a sig-
nificant decrease in lipid peroxidation and an increase in
the activity of endogenous antioxidant defense mechan-
isms, such as SOD and GSH, in rat kidney tissue [42].
The beneficial effects of EPO on renal dysfunction and
hemodynamics have been recently confirmed in large-
animal models of ischemic acute kidney injury (monkeys,
pigs, and dogs [43-46]).
An interesting and widely accepted phenomenon of EPO
is its ability to protect tissues after the onset of injury. Just
like the studies in the brain and heart, the kidney is no
exception. The administration of 5,000 IU/kg of EPO as
late as 6 hours after a 30-min ischemic insult protects the
kidney from dysfunction and injury, with no significant
difference in the protection seen when EPO is adminis-
tered on reperfusion [47].
EPO also is protective against medication-induced
renal dysfunction, facilitating the recovery from cispla-
tin-induced acute kidney injury [48] and attenuation of
renal interstitial inflammation and fibrosis in chronic
cyclosporine nephropathy [49].
Mechanisms
The evidence in favor for a direct anti-inflammatory
effect of EPO is continually increasing and thus reclassi-
fying EPO as a multifunctional tissue-protective cytokine.
Data indicate that EPO may be of benefit in certain dis-
ease models in which excessive inflammation plays a key
role. For instance, EPO has been demonstrated not only
to decrease proinflammatory cytokine production but
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IL-10 after myocardial IRI in rats [25]. A recent study has
shown that EPO administration within 2 hours of a lipo-
polysaccharide (LPS) insult prevented apoptosis, exces-
sive nitric oxide production, peroxynitrite formation, and
tissue hypoxia, but without any significant alterations in
tissue neutrophilia, NF-B activation, or the increased
serum levels of proinflammatory chemokines and
HMGB-1 [4]. Much of this data is consistent with pre-
vious findings, which have shown that EPO (10 IU/ml)
prevents the expression of iNOS protein induced by
interferon-g and LPS in rat oligodendrocytes [50]. In a
model of zymosan-induced nonseptic shock, EPO (1,000
IU/kg) attenuated the degree of systemic injury, and this
effect was attributed to a reduced nitrotyrosine and poly
(ADP-ribose) polymerase staining in the tissue of target
organs and a reduction in the level of circulating cyto-
kines (TNF-a and IL-1b) in the plasma [51]. We have
reported that the administration of EPO (300 IU/kg)
after severe hemorrhage (e.g., upon resuscitation) reduces
the organ injury and dysfunction caused by hemorrhagic
shock. This beneficial effect of EPO was associated with a
reduced activation of apoptosis secondary to prevention
of the activation of caspases -3, -8, and -9 [3]. EPO (1,000
IU/kg/day) also reduces the joint injury and chronic
inflammation in a rat model of type II collagen-induced
arthritis. It is likely that the anti-inflammatory effects of
EPO in this model of chronic inflammation are–at least
in part–secondary to prevention of tissue injury (both
apoptosis and necrosis), which would result in the
reduced formation of proinflammatory cytokines in the
circulation [52]. Finally, both inflammatory and vascular
endothelial cells have been shown to express EPOR
[53,54]. Although EPO and cytokines do not seem to
directly modulate EPOR levels in normal tissue, EPO can
strongly stimulate the expression of its own pharmacolo-
gical target at low oxygen tensions in endothelial cells
[55]. These findings are further supportive of its impor-
tant role in modulating the excessive inflammatory
response associated with IRI.
Many of these observed effects of EPO are dependent
on Janus tyrosine kinase 2-activation (mediated by the
EPOR) and the nuclear translocation of NF-B [56]. In
inflammatory scenarios, EPO may reduce the inflamma-
tion associated with shock and ischemic injury through a
reduction in apoptotic cell death [57] via up-regulation of
the anti-apoptotic proteins Bcl-2 and Bcl-XL [58]. EPO
also prevents the release of the proapoptotic proteins
cytochrome c and caspase-3 from the mitochondrial
membrane by up-regulating the phosphoinositide 3
kinase and protein kinase B (PI3K/Akt) pathway [59-61].
Thus, increasing or decreasing the cytoplasmatic concen-
tration of these proteins, respectively, will result in the
inhibition of apoptosis [62]. In addition, a fairly recent
study showed that up-regulation of the PI3K/Akt path-
way is associated with the enhanced expression of
endothelial nitric oxide synthase (eNOS) in isolated mice
cardiomyocytes, which resulted in increased levels of
nitric oxide [63]. In a more recent study, eNOS has been
shown to integrate with the b common receptor [64], a
receptor that has in recent years been shown to play a
crucial role in EPO-mediated nonhematopoietic effects
[65]. Activation of the b common receptor with EPO
initiates increased interaction between the b common
receptor and eNOS, resulting in the increased formation
of nitric oxide. Nitric oxide not only directly limits the
formation of free radicals but also promotes vasodilata-
tion and could therefore limit hypoxic damage during
vaso-occlusion [66]. In a transgenic mouse model overex-
pressing human EPO, the authors demonstrated that
these mice fail to develop hypertension, stroke, myocar-
dial infarction, or thromboembolism [67] but do have
hematocrit levels of approximately 80% with generalized
vasodilatation [68]. The inhibition of eNOS in these mice
causes 100% mortality within 2 days and hence the gen-
eralized vasodilatation was attributed to an up-regulation
of eNOS expression, increased NO production, and NO-
mediated vascular relaxation compared with wild-type
animals. Similarly, the administration of EPO to wild-
type and eNOS
-/- mice before ischemia resulted in
increased expression of eNOS and decreased infarct size
only in the wild-type mice [63].
Although several experimental data suggest that EPO
can induce cytoprotection through EPOR and/or the b
common receptor as described above, there are still
further investigations required to confirm the identity of
EPO receptor subtypes as well as the different factors
involved in the beneficial effects of EPO in several
experimental models of IRI and inflammation.
Clinical evidence
Considering all of the above-mentioned preclinical data,
EPO is an attractive molecule for evaluation in several
human disease conditions. The first of these conditions to
evaluate EPO as a potential therapy was human stroke
[69]. The purpose of the Göttingen EPO Stroke Study (a
pilot noncontrolled study) was to determine whether EPO
would be safe due to the possibility of raised hematocrit
and subsequently increasing the likelihood of further tran-
sient ischemic attacks during a 30-day follow-up period.
During the 30-day follow-up period hematocrit, hemoglo-
bin, and red blood cell counts all remained normal despite
a high infusion of EPO (100,000 IU over 3 days). This trial
demonstrated that EPO is well tolerated and improves
clinical outcome at 1 month as determined by neurological
scoring and MRI. However, the more recent German Mul-
ticenter EPO Stroke Trial, which was designed to repro-
duce the results of the Göttingen EPO Stroke Study, has
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recombinant tissue plasminogen activator (tPA) is not
advantageous and may even be detrimental [70]. Patients
were infused 40,000 IU of EPO over 30 min within the
first 6 hours after the onset of symptoms and EPO (at a
same dose) was readministered 24 and 48 hours later.
During the 90-day follow-up period, the EPO arm demon-
strated an increased risk of death, intracerebral hemor-
rhage, brain edema, and thromboembolic events.
Moreover, patients who received both EPO and tPA (60%
of patients) were significantly more likely to die than those
receiving EPO only. It is possible that the beneficial effects
of EPO were antagonized by tPA resulting in the higher
mortality. Thus, caution is necessary when clinical trials
with EPO in patients with ischemic stroke are conducted,
and one must be vigilant for known and unknown side
effects of this potential life-saving strategy.
With trauma being the leading cause of mortality and
morbidity in the western world, it accounts for the high-
est incidence of deaths in Americans younger than age
34 years [71]. In critically ill trauma patients, anemia is
very common and the CRIT study highlighted this very
well, demonstrating that critically ill trauma patients
were more likely to be transfused than critically ill non-
trauma patients (55.4% vs. 44.1%) with a greater amount
of blood transfusions (5.8 ± 5.5 units vs. 4.6 ± 4.9 units)
[72]. This led to the hypothesis that treatment with phar-
macological doses of EPO might decrease the exposure
of patients to allogeneic blood and increase the hemoglo-
bin level in anemic critically ill patients. This was essen-
tially the beginning of three randomized studies (EPO-1,
-2, and -3) involving 160, 1,302, and 1,460 patients,
respectively. EPO-1 demonstrated a reduction in red
blood cell transfusion that correlated with an increase in
hemoglobin amongst critically ill patients treated with
EPO [73]. These findings were confirmed in the second
larger trial, EPO-2 [74]. Interestingly, this second trial
demonstrated a survival benefit in critically ill trauma
patients randomized to receive EPO treatment: at day 29
(deaths: placebo 8.9% vs. EPO 4.1%) and day 42 (deaths:
placebo 10.4% vs. EPO 4.8%). However, the significance
of this was not very clear, because the study did not col-
lect specific information on trauma-specific variables that
could have potentially affected patient outcome in the
trauma cohort. In the third randomized study (EPO-3),
admission groups were prospectively identified and ran-
domization was stratified according trauma, medicine
nontrauma and surgery nontrauma [75]. Patients were
treated with EPO (40,000 IU/kg) once per week for
3w e e k s .A sw i t ht h eE P O - 2s t u d y ,as u r v i v a lb e n e f i tw a s
identified in critically ill trauma patients who received
EPO: at day 29 (deaths: placebo 6.7% vs. EPO 3.5%), day
42 (deaths: placebo 7.2% vs. EPO 3.7%), and day 140
(deaths: placebo 9.2% vs. EPO 6.0%). However, on this
occasion there was no reduction in red blood cell trans-
fusion amongst patients treated with EPO despite an
increase in hemoglobin concentration, which actually
resulted in an increase in clinically relevant thrombovas-
cular events (TVE: placebo 12.5% vs. EPO 16.4%). The
data from EPO-3, therefore, suggests that the survival
benefit was independent of any transfusion effects [76].
Moreover, this raises the issue of the tissue protective
effects of EPO being overwhelmed by rising hematocrit if
not controlled properly. Clearly, EPO mimetics that do
not have the ability to raise hematocrit may be an ideal
alternative in this area, such as the recently discovered
pyroglutamate helix B surface peptide [77,78].
Randomized placebo-controlled trials with EPO in
patients with myocardial infarction have been conducted
in the Netherlands, Germany, and Japan [79-82]. Despite
the apparent reduction of infarct size and improvement in
LV function resulting from EPO treatment in animal mod-
els of myocardial infarction, overall these clinical trials did
not demonstrate consistent results regarding LV function
in the presence of EPO treatment. The two Japanese trials
with low-dose EPO treatment, which were small-scale
pilot studies, showed possible improvement of LV func-
tion, but the other two that used high-dose EPO treatment
did not. In particular, the trial with the highest dose of
EPO (approximately 100,000 IU) showed a tendency
toward an increased incidence of adverse events, whereas
the second study demonstrated that a single bolus with
60,000 IU i.v. of EPO was related to less major adverse
cardiovascular events and a favorable clinical safety profile,
although without any improvement in LV ejection frac-
tion. Therefore, according to these recent clinical trials,
the optimal dose of EPO remains to be determined. It can
be speculated that measurement of LV function, such as
LV ejection fraction, might not be the best surrogate mar-
ker to evaluate the possible beneficial effect of EPO during
myocardial infarction. Large-scale clinical trials with a
primary endpoint of cardiovascular events are needed to
elucidate the efficacy of EPO administration as an adjunc-
tive therapy of myocardial infarction. Recently, an open-
label randomized 12-month trial (the Mechanisms of
Erythropoietin Action in the Cardiorenal Syndrome [EPO-
CARES]) had been designed to discern hematopoietic
from nonhematopoietic effects of EPO in patients with the
combination of chronic heart failure and chronic kidney
disease and mild anemia [83]. This study did not show sig-
nificant influence of short- or long-term EPO therapy on
reduced EPC levels in cardiorenal patients; however, this is
not surprising because there are no preclinical data with
EPO in a cardiorenal setting.
The EARLYARF trial was the first prospective, rando-
mized, double-blind, placebo-controlled, parallel-group
trial to study whether early treatment with EPO (500 IU/kg
within 6 hours and again 24 hours later) could prevent the
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Although the trial found that EPO was not associated with
an increase in clinically significant serious adverse events,
unfortunately, the trial found no significant renoprotection
or amelioration of acute kidney injury after intervention
with EPO. At first glance this may seem quite disconcert-
ing; however, on closer inspection it is possible to see that
the EARLYARF trial had several methodological failings.
The major limitation of the trial was the use of biomarkers
(g-glutamyltranspeptidase and alkaline phosphatase) that
have been poorly validated, but at the inception of the trial
w e r et h eo n l ya v a i l a b l eb i o m a r k e r st h a tw e r ec o n f i r m e d
and rapidly measurable for renal injury [85]. It was only
until after the trial was initiated that more relevant makers
o fr e n a li n j u r yw e r ee s t a b l i s h e d( e . g . ,p l a s m an e u t r o p h i l -
gelatinase-associated lipocalin, and urinary kidney injury
molecule-1, interleukin-18, and liver fatty acid-binding-
protein) [86-90]. The use of such poorly understood bio-
markers resulted in the inclusion of a more generalized
critically ill population rather than those patients suspected
of being in any real risk from acute kidney injury. The trial
also included patients with reversible prerenal acute kidney
injury based on biomarkers of injury alone. Despite there
being any biomarker evidence of injury, a large majority of
patients had preserved renal sodium reabsorption. This,
subsequently, reduces the power of the study with respect
to EPO efficacy. In addition, there were some baseline dif-
ferences between placebo and EPO-treated cohorts. The
placebo group was significantly younger than those treated
with EPO, and a significant proportion of the EPO-treated
group (23.8%) had sepsis. Finally, the first administration of
EPO (at 6 hours) was at the later end of the current theore-
tical interval [47] during which an early benefit might be
detected. All in all, these limitations amongst others
demonstrate that using a single composite biomarker with
a brief postinjury profile was insufficient for risk stratifica-
tion in a population with a heterogeneous onset of injury
[84]. A more extensive trial is required, with valid biomar-
kers/endpoints [91], to determine efficacy of EPO in acute
kidney injury.
The most recent trial to be completed and analyzed this
year was the Reduction of Infarct Expansion and Ventricu-
lar Remodeling with EPO After Large Myocardial Infarc-
tion (REVEAL) trial [92]. This trial included 222 patients
with acute ST-segment elevation myocardial infarction
who underwent successful percutaneous coronary inter-
vention. EPO at a dose of 60,000 IU (~700 IU/kg) was
administered within 4 hours of reperfusion. However, the
primary outcome measure–infarct size–was unchanged
between the placebo arm and EPO arm of the study dur-
ing both the first week and at 12 weeks. In fact, the study
revealed that older patients (> 70 years) receiving EPO had
a 41.2% larger infarct size during the first week, suggesting
that caution must be taken if EPO is administered to
patients older than age 70 years, because may patients suf-
fering from not only heart attacks but also stokes and
acute kidney injury are generally within this age range.
Interestingly, as seen in almost all clinical trials with EPO,
the incidence of both adverse and serious adverse events
was significantly higher in the EPO arm (94/125 patients)
than the placebo arm (50/97 patients), with five deaths
due to myocardial infarction, stroke, or stent thrombosis
occurring in the EPO group only.
Alternatively, several large clinical trials of EPO per-
formed to assess potential utility of normalizing the mar-
ginally low hemoglobin concentrations in patients with
breast or head and neck cancers unexpectedly found an
increase in mortality within the EPO arm due to tumor
progression or significant thrombosis [93-95]. This was
b o r n eo u ti nt h eT R E A Ts t u d yw h e r et h ei n c i d e n c eo f
cancer deaths was higher in the EPO-treated group [96].
This is not surprising because preclinical data suggest
that EPO is a very powerful promoter of tumor cell
growth and is able to promote neovascularization to the
site of the tumor, which can potentially increase
metastasis.
It is interesting to consider why there are differences
between animal and clinical studies. The most obvious
assumption is that there are species differences, but the
CRIT study has demonstrated a beneficial outcome with
EPO despite the risk of adverse effects. The dose of EPO
used in these studies also may play a major role. Animal
studies use doses up to 5,000 IU/kg, and in clinical studies
the dose rarely exceeds 1,000 IU/kg in any single adminis-
tration. Timing of administration also may be very impor-
tant; animal studies have taught us that there is a
definitive window of treatment after injury.
Conclusions
During the past decade, several key lines of evidence have
strongly supported the view that endogenous EPO may
play a crucial role in dampening the excessive tissue injury
associated with by IRI and inflammation, but as yet there
is no evidence that EPO may actually accelerate recovery
after injury. Systemic administration of EPO has been
f o u n dt ob ea c t i v ei nal a r g en u m b e ro fa n i m a lm o d e l s
associated with IRI, including stroke, myocardial infarc-
tion, acute kidney injury, hemorrhagic shock, and SIRS.
However, the use of EPO in several large clinical trials for
the treatment of anemia in cancer patients was associated
with increased adverse events. A surgical trauma trial that
showed increased survival in the EPO arm also showed
that this was at the expense of a 40% increase in clinically
significant thrombosis. Thus, although administration of
EPO has potentially valuable tissue protective effects, clini-
cal trials have shown that the administration of EPO is
accompanied by significant adverse effects or demonstrate
poor utility due to inadequate study design. Notably, these
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of EPO, such as those used in the tissue protection proof-
of-concept trials. There is still a need for properly
designed clinical trials to assess the efficacy of EPO beyond
anemia. We recommend that novel adjuvant therapies
should be explored to promote the effectiveness of endo-
genously secreted EPO in critical care settings to restore
EPOs sensitivity at the tissue level. This would limit the
use of high doses of exogenous EPO that can overwhelm
the tissue-protective properties of EPO with its adverse
side-effects.
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